Newly published results of a phase 3 study of baricitinib, a once-daily oral Janus kinase inhibitor for the treatment of moderate to severe rheumatoid arthritis (RA), show that the small-molecule drug provided greater improvements in patient-reported outcomes than either placebo or the biologic adalimumab (Humira).
Newly published results of a phase 3 study of baricitinib, a once-daily oral Janus kinase inhibitor for the treatment of moderate to severe rheumatoid arthritis (RA), show that the small-molecule drug provided greater improvements in patient-reported outcomes (PROs) than either placebo or adalimumab (Humira). The study, funded by Eli Lilly and Incyte Corporation, is published in Annals of the Rheumatic Diseases.
The randomized, double-blind, double-dummy, placebo-controlled and active-controlled, parallel-arm, 52-week study was conducted at 281 centers in 26 countries. A total of 1307 patients were randomized to receive placebo (n = 488), baricitinib at a daily dose of 4 mg (n = 487), or subcutaneously administered adalimumab at a biweekly dose of 40 mg (n = 330) together with existing background therapy, including methotrexate. With primary analysis marked for week 12, patients receiving placebo switched to baricitinib in week 24.
PROs were prespecified as secondary objectives in the study, and included:
A 3- to 4-point change was considered a minimum clinically important difference (MCID). PROs including duration of morning joint stiffness and morning joint stiffness severity, worst tiredness, and worst joint pain numeric rating scales were recorded using a daily electronic diary from day 1 to week 12.
Health-related quality of life was assessed using Medical Outcomes Study Short-Form-36, which assesses 8 domains. The EuroQoL 5-Dimensions Health State Profile was also used, and included a descriptive system of the respondent’s health and a rating of their current health state. The Work Productivity and Activity Impairment Questionnaire-RA was used to measure overall work productivity and impairment of regular activities.
The researchers found the following:
The researchers concluded that patients with RA who were treated with baricitinib experienced greater improvement in most PROs across a variety of domains, compared with patients treated with placebo or adalimumab.
Eli Lilly, sponsor of baricitinib, received a complete response letter from the FDA in April 2017, when the regulatory agency indicated that additional data were necessary in to assess drug safety. Last week, Eli Lilly and the Incyte Corporation announced that they will resubmit their New Drug Application for the drug by the end of January 2018. If approved, baricitinib could exert further pressure on Humira, which already stands to lose RA market share to adalimumab biosimilars, 2 of which are now approved by the FDA.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.